{"prompt": "['MC1575', '13', 'Amendment 2', 'In assessing safety and efficacy of lenvatinib in patients with pheochromocytoma or', 'paraganglioma, and given the wide range and seriousness of reported side effects, we', 'plan to incorporate QOL data while treating our patient cohort in correlation with', 'response outcomes. QOL data will be collected at baseline and every two months on', 'therapy. We propose to use EQ-5D-5L descriptive questionnaire system designed by', 'EuroQol group as well as FACT-G (Functional Assessment of Cancer Therapy-General).', 'The usual starting dose for Lenvatinib in DTC is 24 mg per day (Schlumberger, Tahara et', 'al. 2015). Hypertension is one of the most common side effects seen with lenvatinib use.', 'Hypertension and its complications are usual in catecholamine secreting tumors like', 'paragangliomas and pheochromocytomas. Therefore, a reduced starting dose of 20 mg', 'daily is being proposed for this trial.', '1.4', 'Hypotheses', 'Hypothesis 1: Lenvatinib treatment of patients with advanced malignant', 'pheochromocytoma and paraganglioma may lead to attenuated tumor', 'growth and/or tumor regression (as defined by RECIST criteria - see', 'Section 11.0).', 'Hypothesis 2: Lenvatinib-induced changes in plasma and urinary catecholamine and/or', 'metanephrine levels in patients with advanced, catecholamine secreting', 'pheochromocytoma and paraganglioma may be observed and be', 'predictive of patient objective response to lenvatinib therapy (per RECIST', 'criteria - see Section 11.0).', 'Hypothesis 3: Somatic mutational status (presence of SDHD, SDHB, RET, VHL,', 'neurofibromatosis type-1 in archival tumors) may predict response to', 'lenvatinib therapy.', 'Hypothesis 4: Germline mutational status (detection of SDHD, SDHB, RET, VHL,', \"neurofibromatosis type-1 in patient's PBMCs) may predict response to\", 'lenvatinib therapy.', 'Hypothesis 5: There is no significant deleterious net change in patient reported quality of', 'life during lenvatinib therapy.', 'Protocol Version Date: :16Aug2018']['MC1575', '14', 'Amendment 2', '2.0', 'OBJECTIVES', '2.1', 'Primary objective', 'To determine the anti-tumor activity of lenvatinib (overall response rate; ORR) in', 'patients with metastatic or advanced unresectable pheochromocytomas and', 'paragangliomas', '2.2', 'Secondary objectives', '2.21', 'To determine progression-free survival (PFS)', '2.22', 'To determine overall survival (OS)', '2.23', 'To determine duration of tumor response', '2.24', 'To determine safety and tolerability of lenvatinib', '2.25', 'To assess patient reported quality of life using EQ-5D-5L and FACT-G', '2.3', 'Correlative objectives', '2.31', 'For patients with secretory tumors,', '2.311', 'To examine changes in plasma metanephrine levels and urinary', 'catecholamine and/or metanephrine levels.', '2.312', 'To examine whether lenvatinib-induced changes in plasma', 'metanephrines and urinary catecholamine and/or metanephrine levels', 'during the first cycle of treatment may be associated with objective', 'tumor response.', '2.32', 'To examine associations between tumor response and somatic mutational status', 'in archived tumors, or germline mutational status (presence of SDHD, SDHB,', 'RET, VHL, neurofibromatosis type-1).', 'Protocol Version Date: :16Aug2018']['MC1575', '15', 'Amendment 2', '3.0', 'ELIGIBILITY', '3.1', 'Inclusion Criteria', '3.11', 'Age > >18 years.', '3.12', 'Histologically or cytologically confirmed malignant secretory or non-secretory', 'pheochromocytoma or paraganglioma that is unresectable and deemed', 'inappropriate for alternative local regional therapeutic approaches.', '3.13', 'Measurable disease as defined in Section 11.0.', '3.14', 'ECOG Performance Status (PS) 0, 1, or 2 (Appendix I).', '3.15', 'Life expectancy >24 weeks.', '3.16', 'The following laboratory values obtained 14 days prior to registration.', 'Absolute neutrophil count (ANC) >1500/mm\u00b3', 'White blood cell (WBC) count >3,000/mm\u00b3', 'Platelet count >100,000/mm\u00b3', 'Hemoglobin >9.0 g/dL (5.6mmol/L)', 'NOTE: Transfusions are not allowed 7 days prior to registration', 'Total bilirubin <1.5 X upper limit of normal (ULN)', '(or total bilirubin <3.0 X ULN with direct bilirubin <1.5 X ULN in patients', \"with well-documented Gilbert's Syndrome)\", 'Aspartate transaminase (AST/SGOT) <2.5 X ULN', 'Creatinine <1.5 X ULN', 'Urine protein/creatinine ratio 1 OR 24-hour urine protein <1.5 gram', '3.17', 'Negative pregnancy test done 7 days prior to registration, for women of', 'childbearing potential only.', '3.18', 'Blood pressure (BP) <150 mmHg (systolic) and <90 mmHg (diastolic). Initiation', 'or adjustment of BP medication is permitted prior to registration provided that', 'the average of three BP readings at a visit prior to registration is <150/90 mmHg.', 'NOTE: All patients with secretory pheochromocytoma or paraganglioma are', 'REQUIRED to: 1) be evaluated in consultation by a hypertension specialist with', 'specific experience in the management of hypertension in the setting of', 'catecholamine-secreting tumors (usually an endocrinologist, nephrologist, or a', 'cardiologist), and in the setting of hormone-associated hypertension) receive', 'a-', 'and -adrenergic blockade for at least 7-14 days prior to initiation of lenvatinib', '(see Appendix IV for guidelines regarding proper a- and \u00df-blockade). The', 'hypertension specialist of record for each patient should be committed to closely', 'following the patient during the clinical study with evaluation by said specialist', 'required at Cycle 1 and 2 and thereafter on an as needed basis. Please see', 'Appendix IV for guidelines on hypertension evaluation, follow up and', 'management.', 'Please note that this is a critical patient safety issue and that no exceptions to', 'this approach are permitted.', '3.19a', 'Provide written informed consent.', 'Protocol Version Date:16Aug2018']\n\n###\n\n", "completion": "END"}